COVID-19-associated fungal infections

M Hoenigl, D Seidel, R Sprute, C Cunha… - Nature …, 2022 - nature.com
Abstract Coronavirus disease 2019 (COVID-19)-associated invasive fungal infections are an
important complication in a substantial number of critically ill, hospitalized patients with …

A visual and comprehensive review on COVID-19-associated pulmonary aspergillosis (CAPA)

S Feys, MP Almyroudi, R Braspenning, K Lagrou… - Journal of Fungi, 2021 - mdpi.com
Coronavirus disease 19 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a severe
fungal infection complicating critically ill COVID-19 patients. Numerous retrospective and …

[HTML][HTML] ESCMID COVID-19 living guidelines: drug treatment and clinical management

M Bartoletti, O Azap, A Barac, L Bussini… - Clinical microbiology …, 2022 - Elsevier
Abstract Scope In January 2021, the ESCMID Executive Committee decided to launch a new
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …

[HTML][HTML] Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European …

J Prattes, J Wauters, DR Giacobbe… - Clinical Microbiology …, 2022 - Elsevier
Abstract Objectives Coronavirus disease 2019 (COVID-19)-associated pulmonary
aspergillosis (CAPA) has emerged as a complication in critically ill COVID-19 patients. The …

Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study

S Hatzl, AC Reisinger, F Posch, J Prattes, M Stradner… - Critical Care, 2021 - Springer
Abstract Background Coronavirus disease 19 (COVID-19)-associated pulmonary
aspergillosis (CAPA) emerged as important fungal complications in patients with COVID-19 …

COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion

FL van de Veerdonk, RJM Brüggemann… - The Lancet …, 2021 - thelancet.com
Invasive pulmonary aspergillosis is emerging as a secondary infection in patients with
COVID-19, which can present as alveolar disease, airway disease (ie, invasive Aspergillus …

Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease

M Hoenigl, A Arastehfar, MC Arendrup… - Clinical Microbiology …, 2024 - Am Soc Microbiol
Fungal infections are on the rise, driven by a growing population at risk and climate change.
Currently available antifungals include only five classes, and their utility and efficacy in …

COVID-19-associated pulmonary aspergillosis (CAPA)

G Dimopoulos, MP Almyroudi… - Journal of Intensive …, 2021 - mednexus.org
Invasive Pulmonary Aspergillosis (IPA) has been recognized as a possible secondary
infection complicating Coronavirus disease 2019 (COVID-19) and increasing mortality. The …

COVID-19-associated pulmonary aspergillosis, fungemia, and pneumocystosis in the intensive care unit: a retrospective multicenter observational cohort during the …

S Bretagne, K Sitbon, F Botterel, S Dellière… - Microbiology …, 2021 - Am Soc Microbiol
The aim of this study was to evaluate diagnostic means, host factors, delay of occurrence,
and outcome of patients with COVID-19 pneumonia and fungal coinfections in the intensive …

A Pathology-based Case Series of Influenza-and COVID-19–associated Pulmonary Aspergillosis: The Proof Is in the Tissue

L Vanderbeke, C Jacobs, S Feys… - American Journal of …, 2023 - atsjournals.org
Rationale: Invasive pulmonary aspergillosis has emerged as a frequent coinfection in
severe coronavirus disease (COVID-19), similarly to influenza, yet the clinical invasiveness …